173 related articles for article (PubMed ID: 38040820)
1. The influence of thionamides on intra-thyroidal uptake of
Happel C; Bockisch B; Leonhäuser B; Sabet A; Grünwald F; Groener D
Sci Rep; 2023 Dec; 13(1):21190. PubMed ID: 38040820
[TBL] [Abstract][Full Text] [Related]
2. The influence of thyroid hormone medication on intra-therapeutic half-life of
Happel C; Kranert WT; Bockisch B; Sabet A; Grünwald F; Groener D
Sci Rep; 2022 Aug; 12(1):13925. PubMed ID: 35978004
[TBL] [Abstract][Full Text] [Related]
3. Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases.
Happel C; Kranert WT; Ackermann H; Binse I; Bockisch B; Gröner D; Herrmann K; Grünwald F
Endocrine; 2019 Mar; 63(3):537-544. PubMed ID: 30599051
[TBL] [Abstract][Full Text] [Related]
4. Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of
Happel C; Kranert WT; Gröner D; Baumgarten J; Halstenberg J; Bockisch B; Sabet A; Grünwald F
Endocrine; 2021 Jul; 73(1):125-130. PubMed ID: 33439464
[TBL] [Abstract][Full Text] [Related]
5. [Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves' disease].
Halstenberg J; Kranert WT; Korkusuz H; Mayer A; Ackermann H; Grünwald F; Happel C
Nuklearmedizin; 2018 Apr; 57(2):43-49. PubMed ID: 29590674
[TBL] [Abstract][Full Text] [Related]
6. Graves' disease and radioiodine therapy. Is success of ablation dependent on the choice of thyreostatic medication?
Kobe C; Weber I; Eschner W; Sudbrock F; Schmidt M; Dietlein M; Schicha H
Nuklearmedizin; 2008; 47(4):153-6. PubMed ID: 18690374
[TBL] [Abstract][Full Text] [Related]
7. Methimazole discontinuation before radioiodine therapy in patients with Graves' disease.
Zakavi SR; Khazaei G; Sadeghi R; Ayati N; Davachi B; Bonakdaran S; Jabbari Nooghabi M; Moosavi Z
Nucl Med Commun; 2015 Dec; 36(12):1202-7. PubMed ID: 26426965
[TBL] [Abstract][Full Text] [Related]
8. Thionamides alter the efficacy of radioiodine treatment in patients with Graves' disease.
Koroscil TM
South Med J; 1995 Aug; 88(8):831-6. PubMed ID: 7631208
[TBL] [Abstract][Full Text] [Related]
9. Influence of prior carbimazole on the outcome of radioiodine therapy in pediatric and adolescent Graves' disease.
Ballal S; Soundararajan R; Singh H; Garg A; Chopra S; Bal C
Nucl Med Commun; 2015 Jun; 36(6):566-72. PubMed ID: 25757198
[TBL] [Abstract][Full Text] [Related]
10. [Radioiodine therapy of autonomously functioning thyroid nodules and Graves' disease].
Guhlmann CA; Rendl J; Börner W
Nuklearmedizin; 1995 Feb; 34(1):20-3. PubMed ID: 7724360
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves' disease.
Moura-Neto A; Mosci C; Santos AO; Amorim BJ; de Lima MC; Etchebehere EC; Tambascia MA; Ramos CD; Zantut-Wittmann DE
Clin Nucl Med; 2012 Jun; 37(6):550-4. PubMed ID: 22614185
[TBL] [Abstract][Full Text] [Related]
14. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
[TBL] [Abstract][Full Text] [Related]
15. High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in Graves' disease.
Zantut-Wittmann DE; Ramos CD; Santos AO; Lima MM; Panzan AD; Facuri FV; Etchebehere EC; Lima MC; Tambascia MA; Camargo EE
Nucl Med Commun; 2005 Nov; 26(11):957-63. PubMed ID: 16208172
[TBL] [Abstract][Full Text] [Related]
16. The effect of short-term treatment with lithium carbonate on the outcome of radioiodine therapy in patients with long-lasting Graves' hyperthyroidism.
Sekulić V; Rajić M; Vlajković M; Ilić S; Stević M; Kojić M
Ann Nucl Med; 2017 Dec; 31(10):744-751. PubMed ID: 28895066
[TBL] [Abstract][Full Text] [Related]
17. Radioiodine therapy versus antithyroid medications for Graves' disease.
Ma C; Xie J; Wang H; Li J; Chen S
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD010094. PubMed ID: 26891370
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors for the outcomes of Graves' disease patients with radioactive iodine (131I) treatment.
Xing YZ; Zhang K; Jin G
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31840740
[TBL] [Abstract][Full Text] [Related]
19. An update on the medical treatment of Graves' hyperthyroidism.
Marinò M; Latrofa F; Menconi F; Chiovato L; Vitti P
J Endocrinol Invest; 2014 Nov; 37(11):1041-8. PubMed ID: 25185644
[TBL] [Abstract][Full Text] [Related]
20. Effect of Lugol's solution on
Chai J; Zhang R; Zheng W; Zhang G; Jia Q; Tan J; Meng Z; Wang R
Clin Exp Med; 2023 Jul; 23(3):825-831. PubMed ID: 35840869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
